Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Deferred Revenue (2023 - 2026)

bioAffinity Technologies has reported Current Deferred Revenue over the past 4 years, most recently at $31140.0 for Q1 2026.

  • Quarterly Current Deferred Revenue rose 27.6% to $31140.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $31140.0 through Mar 2026, up 27.6% year-over-year, with the annual reading at $23827.0 for FY2025, 2.36% down from the prior year.
  • Current Deferred Revenue was $31140.0 for Q1 2026 at bioAffinity Technologies, up from $23827.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $42750.0 in Q2 2023 and troughed at $23827.0 in Q4 2025.
  • The 4-year median for Current Deferred Revenue is $28154.5 (2024), against an average of $30072.1.
  • Year-over-year, Current Deferred Revenue tumbled 38.87% in 2024 and then surged 55.36% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $33058.0 in 2023, then fell by 26.18% to $24404.0 in 2024, then decreased by 2.36% to $23827.0 in 2025, then soared by 30.69% to $31140.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Current Deferred Revenue are $31140.0 (Q1 2026), $23827.0 (Q4 2025), and $37915.0 (Q3 2025).